Login
$DNLI
$18.08 -$0.66 (3.52%) Live

$DNLI SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
03 Nov 2026 10-Q
03 Nov 2026 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif. – November 3, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2026, and provided business highlights.

09 Sep 2026 Form 4: Chin Peter Scott, Chief Medical Officer

Sold 1,654 shares ($36.9K)

04 Sep 2026 144
04 Sep 2026 Form 4: Thornberry Nancy, Director

Sold 11,439 shares ($262K)

03 Sep 2026 Form 4: Schuth Alexander O., COFO and Secretary

Sold 2,768 shares ($64.9K)

02 Sep 2026 144
01 Sep 2026 144
14 Aug 2026 Form 4: Watts Ryan J., Director

Gave 32,220 shares as a gift

13 Aug 2026 Form 4: Schuth Alexander O., COFO and Secretary

Sold 2,857 shares ($71.6K)

11 Aug 2026 144
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif. – August 6, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2026, and provided business highlights.

04 Aug 2026 SCHEDULE 13G/A
28 Jul 2026 8-K: Completion of Acquisition or Disposition of Assets

On July 27, 2026, Denali Therapeutics Inc. (the “Company”) completed the previously disclosed sale (the “Sale”) of its Rare Pediatric Disease Priority Review Voucher (the “PRV”) to a large pharmaceutical company. The Company received the...

08 Jul 2026 SCHEDULE 13G/A
18 Jun 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

SOUTH SAN FRANCISCO, Calif., – June 18, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195...

05 Jun 2026 Form 4: Flatley Jay T, Director

Received 6,408 shares as a grant or award · Granted 19,226 Stock Option (right to buy)

05 Jun 2026 Form 4: Klein Peter S, Director

Received 6,408 shares as a grant or award · Granted 19,226 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support